Search Results

Physical Exercise: A Promising Treatment Against Organ Fibrosis.

• Authors : Ma, Xiaojie; Liu, Bing; Jiang, Ziming

Subjects: REACTIVE oxygen species; EXERCISE therapy; EXTRACELLULAR matrix

• Source: International Journal of Molecular Sciences; Jan2025, Vol. 26 Issue 1, p343, 22p

Record details

Interleukin-11 signaling plays limited roles for liver fibrosis in a mouse model of metabolic dysfunction-associated steatohepatitis.

• Authors : Tsuchiya, Yuichi^1,2 (AUTHOR) ; Nishina, Takashi¹ (AUTHOR); Komazawa-Sakon, Sachiko¹ (AUTHOR)

Subjects: *HEPATIC fibrosis; *CHRONIC active hepatitis; *ETIOLOGY of diseases

• Source: Biochemical & Biophysical Research Communications. Dec2024, Vol. 739, pN.PAG-N.PAG. 1p.

Record details

Association between liver fibrosis and the in-hospital mortality in patients with sepsis-induced coagulopathy

• Authors : Shi, Yiyi; Meng, Zhizhen; Qian, Songzan

• Source: BMC Infectious Diseases. October 10, 2024, Vol. 24 Issue 1

Record details

Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison.

• Authors : Vesković, Milena; Pejović, Milka; Šutulović, Nikola

Subjects: FATTY liver; HEPATIC fibrosis; NON-alcoholic fatty liver disease

• Source: International Journal of Molecular Sciences; Jul2024, Vol. 25 Issue 13, p7405, 19p

Record details

Three-dimensional MR Elastography and Two-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension.

Subjects: PORTAL hypertension; ACOUSTIC radiation force impulse imaging; DIGESTIVE system diseases

• Source: Hepatitis Weekly; 1/29/2024, p981-981, 1p

Record details

New Findings from Hallym University Describe Advances in Alcoholic Liver Disease (Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease).

Subjects: KILLER cells; LIVER cells; DIGESTIVE system diseasesSOUTH Korea

• Source: Hepatitis Weekly; 12/8/2023, p432-432, 1p

Record details

Agricola

Record details

Herpetetrone nanosuspensions enhance drug solubility and bioavailability to improve anti-hepatic fibrosis effects.

• Authors : Yuji Zhong^1,2; Lingyu Hang¹; Fang Wang^1,2

Subjects: *DRUG bioavailability; *ZETA potential; *ORAL drug administration

• Source: Journal of Microencapsulation. Dec2023, Vol. 40 Issue 8, p587-598. 12p.

Record details

New Findings in Liver Diseases and Conditions Described from National Hospital Organization Yokohama Medical Center (Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic...).

Subjects: LIVER diseases; PUBLIC hospitals; NON-alcoholic fatty liver diseaseYOKOHAMA-shi (Japan); JAPAN

• Source: Hepatitis Weekly; 11/21/2023, p421-421, 1p

Record details

Chronic liver diseases: From development to novel pharmacological therapies: IUPHAR Review 37.

• Authors : Borrello, Maria Teresa; Mann, Derek

Subjects: LIVER diseases; HEPATIC fibrosis; CHRONIC diseases

• Source: British Journal of Pharmacology; Nov2023, Vol. 180 Issue 22, p2880-2897, 18p

Record details